Abstract
Therapy for cancer patients with biologically active immune modulators is attractive but has met with limited clinical success. Interleukin-2 (IL2) stimulates T-cells and natural killer (NK) cells to kill tumor cells and levamisole (LMS) is an immunostimulant which has been shown to increase NK cells and activated T-cells in patients receiving this adjuvantly along with 5FU for Stage III colon cancer. This study was designed to evaluate whether treatment with LMS prior to IL2 would provide synergistic activity and improve response rates. Four patients with advanced malignancies were treated with LMS at 50mg po TID for 3 days followed on day 4 with 600,000 units/kg IL2 as a single iv bolus. This treatment was repeated weekly until progression. Serum soluble IL2 receptor (sIL2R) and interferon-γ levels were monitored throughout the treatment course as markers of immune activation. All patients had eventual progression of disease. Toxicity was minimal with Grade II orthostatic hypotension the major consequence of therapy. The pattern of sIL2R levels in 3/4 patients revealed a steady increase over the several weeks of therapy, indicating ongoing immunostimulation (r =0.53 , p= 0.001). Short-term treatment with LMS, however, resulted in a significant and consistent decreases in sIL2R levels (2198 U/ml vs. 1969 U/ml, p=0.001) in all patients. In conclusion, LMS/IL2 in the dose and schedule utilized here was not clinically effective. However, LMS reduced sIL2R levels immediately following a three-day course. This reduction in sIL2R by LMS may improve the possibility of response to IL2 by facilitating a decrease in inhibitory sIL2R. Combinations of these two agents should continue to be investigated as potential synergistic anti-tumor agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Turowski RC, Triozzi PL. Application of chemical im-munomodulators to the treatment of cancer and AIDS. Cancer Invest 1994; 12: 620.
Grimm EA, Mazumber A, Zhang HZ, Rosenbeg SA. Lymphocyte-activated killing phenomenon: lysis of natural killer resistant fresh solid tumor cells by interleukin-2 acti-vated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823.
3. Rosenberg SA, Lotze MT, Yang JC. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474.
Atkins MB, Mier JW eds. Therapeutic applications of interleukin-2, New York, NY, Marcel Dekker, Inc., 1993.
van Haelst-Pisani CM, Pisani RJ, Kovach JS. Cancer im-munotherapy: current status of treatment with interleukin-2 and lymphokine-activated killer cells. Mayo Clin Proc 1989; 64: 451.
Renoux G, Renoux M. Effet immunostimulant d'un imidoth-iazole dans l'immunisation des souris contre l'infection par Brucella abortus. CR Acad Sci 1971; 272D: 349.
Moertel CG, Fleming TR, McDonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adju-vant therapy of resected colon carcinoma. New Engl J Med 1990; 322: 352.
Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel car-cinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447.
Windle R, Bell PRF, Shaw D. Five year results of a ran-domized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 569.
Chrisp P, McTavish D. Levamisole/fluorouracil: A review of their pharmacology and adjuvant therapeutic use in colorectal cancer. Drugs & Aging 1991; 4: 317.
Janik J, Kopp WC, Smith JW, Longo DL, Alvord G, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, Ewel CH, Hursey J, Urba WJ. Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol 1993; 11: 125.
Holcombe RF, Stewart RM, Betzing KW, Kannan K. Alter-ation in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil. Cancer Immunol Immunother 1994; 34: 394.
13. DeBrander M Vandebroek J, Wassenaar H, DeCree J, Braisier A, Demoen B, DeRidder R, Jagers E, Roels V, Vogels O. Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU. Anticancer Research 1995; 15: 2271.
Holcombe RF, Stewart RM, Kannan K. Levamisole is syner-gistic with IL12 in the stimulation of Th1 cells. Blood 1994; 83: 431a.
Redondo JM, Lopex-Guerrero JA, Fresno M. Potentiation of interleukin-2 activity by levamisole and imidazole. Immunol Lett 1987; 14: 111.
Obiri NI, Dupere SL, Pruett SB, Lackey A, Emma D, O'Connor TE. Levamisole meets sulfhydryl requirements of CTLL-2 cells and mediates enhanced proliferative response to mitogen stimulation without increasing interleukin-2 produc-tion. J Biol Response Mod 1990; 9: 288.
Call TG, Creagan ET, Frytak S, Buckner JC, van Haelst-Pisani C, Homburger HA, Katzmann JA. Phase I trial of combined recombinant interleukin-2 with levamisole in patients with advanced malignant disease. Am J Clin Oncol 1994; 17: 344.
Ahmed FY, Leonard GA, A'Hern R, Taylor AE, Lorentzos A, Atkinson H, Moore J, Nicolson MC, Riches PG, Gore ME. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. Br J Cancer 1996; 74: 1109.
Malek TR, Ashwell JD. Interleukin 2 upregulates expression of its receptor on a T cell clone. J Exp Med 1985; 161: 1575.
Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Int Med 1990; 113: 619.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holcombe, R.F., Li, A. & Stewart, R.M. Levamisole and Interleukin-2 for advanced malignancy. Biotherapy 11, 255–258 (1998). https://doi.org/10.1023/A:1008099612354
Issue Date:
DOI: https://doi.org/10.1023/A:1008099612354